The dynamics of HER2-low expression during breast cancer progression

被引:0
作者
Sarah Anderson
Brooke Baxter Bartow
Gene P. Siegal
Xiao Huang
Shi Wei
机构
[1] The University of Alabama at Birmingham,Department of Pathology
[2] The University of Kansas Medical Center,Department of Pathology and Laboratory Medicine
来源
Breast Cancer Research and Treatment | 2023年 / 201卷
关键词
Breast cancer; HER2-low; Immunohistochemistry; In situ hybridization; Amplification; Overexpression;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:437 / 446
页数:9
相关论文
共 151 条
[21]  
Tolaney SM(2021)HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer Breast Cancer Res Treat 190 155-4
[22]  
Cortes J(2022)Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer JAMA Oncol 8 1177-1082
[23]  
Morganti S(2022)Examination of low ERBB2 protein expression in breast cancer tissue JAMA Oncol 8 1-336
[24]  
Ferraro E(2022)HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles Mod Pathol 35 1075-783
[25]  
Nicolò E(2022)HER2-low breast cancers Am J Clin Pathol 157 328-undefined
[26]  
Boscolo Bielo L(2022)Discordance between immunohistochemistry and Erb-B2 receptor tyrosine kinase 2 mRNA to determine human epidermal growth factor receptor 2 low status for breast cancer J Mol Diagn 24 775-undefined
[27]  
Curigliano G(2022)HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment NPJ Breast Cancer 8 66-undefined
[28]  
Tarantino P(undefined)undefined undefined undefined undefined-undefined
[29]  
Modi S(undefined)undefined undefined undefined undefined-undefined
[30]  
Jacot W(undefined)undefined undefined undefined undefined-undefined